Use of dihydroimidazolones for the treatment of dogs

Abstract

The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.

1 - 11 . (canceled) 
     
     
         12 .- 31 . (canceled) 
     
     
         32 . A method for treating a behavioral in a dog, comprising administering a sufficient amount of [1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] or a physiological salt thereof, to a dog with a behavioral abnormality, to treat said behavioral abnormality. 
     
     
         33 . The method of  claim 32 , wherein said [1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] or a physiological salt thereof is administered to the dog once a day. 
     
     
         34 . The method of  claim 32 , wherein said 1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-1,2-one or a physiological salt thereof is administered to the dog at least once a day. 
     
     
         35 . The method of  claim 32 , wherein said [1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] or a physiological salt thereof is orally administered. 
     
     
         36 . The method of  claim 32 , wherein said [1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] or a physiological salt thereof is administered at a dose of from 1 to 200 mg/kg per day. 
     
     
         37 . The method of  claim 35 , wherein said [1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] or a physiological salt thereof is administered at a dose of from 1 to 200 mg/kg per day. 
     
     
         38 . The method of  claim 32 , wherein said behavioral abnormality is drug-resistant. 
     
     
         39 . The method of  claim 32 , wherein an add-on treatment is also administered to the dog. 
     
     
         40 . The method of  claim 33 , wherein an add-on treatment is also administered to the dog. 
     
     
         41 . The method of  claim 34 , wherein an add-on treatment is also administered to the dog. 
     
     
         42 . The method of  claim 35 , wherein an add-on treatment is also administered to the dog. 
     
     
         43 . The method of  claim 36 , wherein an add-on treatment is also administered to the dog. 
     
     
         44 . The method of  claim 36 , wherein an add-on treatment is also administered to the dog. 
     
     
         45 . The method of  claim 32 , wherein such treatment results in fewer side effects. 
     
     
         46 . The method of  claim 33 , wherein such treatment results in fewer side effects. 
     
     
         47 . The method of  claim 34 , wherein such treatment results in fewer side effects. 
     
     
         48 . The method of  claim 35 , wherein such treatment results in fewer side effects. 
     
     
         49 . The method of  claim 36 , wherein such treatment results in fewer side effects. 
     
     
         50 . The method of  claim 37 , wherein such treatment results in fewer side effects. 
     
     
         51 . The method of  claim 38 , wherein such treatment results in fewer side effects.